

Amicus, Wednesday August 31, 2022, 07.30-08.30, Hall Jerusalem

### **The FACES\* of Fabry disease**

\*FACES: Fabry Associated Clinical Events – renal, cardiac and cerebrovascular outcomes

Welcome and introductions

*Ana Jovanovic, Salford, United Kingdom*

Patient perspectives: Experiences with FACES

- Two people living with Fabry disease share their experiences of FACES in a structured interview led by Ana Jovanovic
- Personal impact of FACES on the people living with Fabry disease and their families

*People living with Fabry disease and Ana Jovanovic, Salford, United Kingdom*

Session 1: Overview of FACES

- Presentation of an overview of FACES, including:
  - The multisystemic nature of Fabry disease and preclinical manifestations
  - An introduction to FACES, including use as a treatment outcome (not just as a clinical trial tool) and impact on clinical management
  - The effect of timely treatment in Fabry disease and the potential impact on FACES (including morbidity and mortality)
  - Cardiac FACES – impact on QoL and correlation with other measures, based on clinical experience

*Peter Nordbeck, Würzburg, Germany*

Session 2: Incidence of FACES during migalastat treatment

- Presentation of FACE incidence in patients receiving migalastat, including:
  - Overview of previous data in the literature surrounding FACE incidence
  - Incidence of FACES during a long-term post-hoc integrated analysis:
    - Overall incidence and incidence by event category (renal, cardiac and cerebrovascular)
    - Factors affecting time to first FACE
    - Association between baseline variables and rate of FACES (highlighting the importance of timely treatment initiation to manage disease)
  - followME baseline data – comparative history of FACES and comorbidities across arms

*Gere Sunder-Plassmann, Vienna, Austria*

Live Q&A

*Moderated Ana Jovanovic with Peter Nordbeck and Gere Sunder-Plassmann*

---

sponsored by

